A Randomized, Double-blind Study Evaluating the Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor and Its Active Metabolite (AR-C124910XX) in Patients With ST-segment Elevation Myocardial Infarction and Non-ST-segment Elevation Myocardial Infarction

Trial Profile

A Randomized, Double-blind Study Evaluating the Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor and Its Active Metabolite (AR-C124910XX) in Patients With ST-segment Elevation Myocardial Infarction and Non-ST-segment Elevation Myocardial Infarction

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Ticagrelor (Primary) ; Morphine
  • Indications Myocardial infarction
  • Focus Pharmacokinetics
  • Acronyms IMPRESSION
  • Most Recent Events

    • 21 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Oct 2015 Results (n=70) published in the European Heart Journal
    • 01 Jan 2015 Trial design presented at Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top